SMAD5 and prostate cancer: It has been reported in prostate cancer that integrin αvβ3 and CD44 pathways function in osteoclastogenesis via a RUNX2/Smad5-signaling axis [39], which provides evidence for RUNX2-related bone destruction in MM.